GENTIAN DIAGNOSTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38 NOK | +1.06% |
|
-1.55% | -8.43% |
| 30/04 | Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 30/04 | Transcript : Gentian Diagnostics ASA, Q1 2024 Earnings Call, Apr 30, 2024 |
Presenter SpeechHilja Ibert (Executives)Good morning, and welcome to the Q1 presentation of Ge...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Gentian Diagnostics ASA is a Norway-based company within health care sector. The Company develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Companyâs product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The Company is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
Calendar
29/08/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
38
NOK
Average target price
57
NOK
Spread / Average Target
+50.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.43% | 5.48Cr | |
| -4.67% | 1.23TCr | |
| -5.19% | 814.08Cr | |
| +28.50% | 562.13Cr | |
| -8.09% | 424.41Cr | |
| -55.31% | 306.33Cr | |
| +13.49% | 275.67Cr | |
| -1.34% | 240.89Cr | |
| +32.24% | 222.74Cr | |
| -3.55% | 186.6Cr |
- Stock Market
- Equities
- GENT Stock
- News Gentian Diagnostics
- Transcript : Gentian Diagnostics ASA, Q1 2024 Earnings Call, Apr 30, 2024